OneSource Specialty Pharma Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 16 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹17.8K Cr
OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29. OneSource expects meaningful contribution from biologics business starting FY27 and FY28, with commercial manufacturing set to begin post-FY28, likely FY29 onwards.
From OneSource Specialty Pharma Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,535
Market Cap
₹17.8K Cr
How does OneSource Specialty Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare OneSource Specialty Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
OneSource Specialty Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹428 Cr, net profit ₹5 Cr.
Full financials →📊 Revenue & Sales Performance
- →OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29.
- →The company reiterated its FY28 guidance of US$400 million revenue and 40% EBITDA margin.
- →Expansion of injectable and soft gel capacities, including three DDC lines by end of FY27, will drive sequential quarter-on-quarter revenue and EBITDA improvement.
- →Demand-supply gap expected to persist for at least the next 2 years, with high customer demand and capacity reservations from clients.
- →Biologics business shows strong funnel with agreements expected in FY27 and meaningful contributions in FY28, indicating a long runway for growth.
- →Growing markets like Brazil, Saudi Arabia, and Turkey, along with emerging markets, offer significant untapped revenue opportunities.
- →Soft gel capacity expected to be fully utilized by end of the current year, with further expansions planned subsequently.
📈 Profitability & Margins
- →OneSource expects meaningful contribution from biologics business starting FY27 and FY28, with commercial manufacturing set to begin post-FY28, likely FY29 onwards.
- →FY28 revenue guidance is reaffirmed at US$400 million with an EBITDA margin of around 40%.
- →Sequential quarterly revenue and EBITDA improvements are expected due to new capacity coming online, including two additional DDC (drug device combination) lines by end of FY27.
- →Capacity expansions in soft gels and injectables will drive growth and utilization, with soft gel capacity fully utilized by end of this year or early next year.
- →EBITDA in Q4 FY26 showed strong operating leverage with margins expanding 1,550 basis points QoQ.
- →FY26 adjusted PAT was INR739 million with a full year EPS of INR6.5; FY27 and beyond expected to show scaling profits and operating leverage.
- →The long-term target includes a 50%+ ROCE medium term, indicating strong future profitability.
🏗️ Capital Expenditure Plans
- →The company is heavily investing in capacity expansion, particularly in the injectable (DDC) and soft gelatine segments to support future growth.
- →A fourth injectable line is being introduced in Unit 2, featuring advanced capabilities like handling high viscosity pre-filled syringes.
- →Two additional injectable lines are planned for installation within the year, with three lines expected to be operational by end of FY27.
- →Capacity expansion also includes upgrading batch sizes from 200 liters to up to 750–1,000 liters, increasing output by 2.5x.
- →The capex for these expansions is fully funded through incremental domestic and international borrowings.
- →Earlier plans for related party transactions involving Steriscience and Brooks have been deferred, with a potential revisit in around two years.
- →The capital investments aim to scale towards the company's $400 million revenue target by FY28 and beyond.
💰 Fundraising & Capital Structure
- →All capacity expansions are fully funded through incremental borrowings from domestic and international banking relationships.
- →The company has lowered its overall cost of borrowing to below 9%, down by 210 basis points compared to the prior year.
- →No mention of current or planned equity fundraising in the disclosed call; focus is on debt-funded capacity expansion.
- →Management indicated potential inorganic elements for growth beyond the $400 million target but did not specify fundraising modes.
- →No announced new equity issuance; emphasis remains on organic growth and existing funding channels for expansion.
📋 Order Book & Pipeline
- →The company is fully committed to its current capacity, with strong visibility of robust demand across markets where approvals exist or are expected.
- →Customers have secured capacity reservations through upfront fees and take-or-pay contracts, indicating a firm orderbook on capacity.
- →Demand-supply gap expected to persist for at least the next two years, reflecting strong pending orders and order pipeline.
- →New manufacturing lines (two additional lines scheduled this year and another next year) are being added to meet this demand.
- →Capacity expansions underway in commercial manufacturing, particularly injectable lines, expected to start contributing beyond FY28.
- →On Semaglutide and GLP products, demand from multiple global generic and regional partners is strong but specific break-up of orders is confidential.
- →Overall, orderbook and pending orders are stable and growing with increasing capacity utilization anticipated by end of current fiscal year.
Key Metrics
Frequently Asked Questions
What were OneSource Specialty Pharma Ltd Q4 FY26 results?
OneSource expects strong growth in FY27 and FY28, with meaningful revenue contributions starting FY27 and commercial biologics manufacturing beginning FY29. OneSource expects meaningful contribution from biologics business starting FY27 and FY28, with commercial manufacturing set to begin post-FY28, likely FY29 onwards.
What is OneSource Specialty Pharma Ltd share price analysis?
OneSource Specialty Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,817 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Specialty Pharma Ltd planning capital expenditure?
The company is heavily investing in capacity expansion, particularly in the injectable (DDC) and soft gelatine segments to support future growth.
Keep OneSource Specialty Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.